Personalis Gross Margin 2018-2026 | PSNL
Current and historical gross margin for Personalis (PSNL) over the last 10 years. The current gross profit margin for Personalis as of March 31, 2026 is %.
| Personalis Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2026-03-31 | $0.06B | $0.01B | 14.29% |
| 2025-12-31 | $0.07B | $0.02B | 23.19% |
| 2025-09-30 | $0.07B | $0.02B | 27.54% |
| 2025-06-30 | $0.08B | $0.03B | 32.10% |
| 2025-03-31 | $0.09B | $0.03B | 33.33% |
| 2024-12-31 | $0.09B | $0.03B | 31.40% |
| 2024-09-30 | $0.09B | $0.03B | 30.34% |
| 2024-06-30 | $0.08B | $0.02B | 25.93% |
| 2024-03-31 | $0.08B | $0.02B | 24.00% |
| 2023-12-31 | $0.07B | $0.02B | 24.32% |
| 2023-09-30 | $0.07B | $0.02B | 21.13% |
| 2023-06-30 | $0.07B | $0.01B | 20.59% |
| 2023-03-31 | $0.07B | $0.01B | 18.84% |
| 2022-12-31 | $0.07B | $0.01B | 18.46% |
| 2022-09-30 | $0.07B | $0.02B | 26.09% |
| 2022-06-30 | $0.08B | $0.02B | 31.58% |
| 2022-03-31 | $0.08B | $0.03B | 35.00% |
| 2021-12-31 | $0.09B | $0.03B | 36.05% |
| 2021-09-30 | $0.09B | $0.03B | 34.12% |
| 2021-06-30 | $0.08B | $0.03B | 31.33% |
| 2021-03-31 | $0.08B | $0.02B | 28.75% |
| 2020-12-31 | $0.08B | $0.02B | 25.64% |
| 2020-09-30 | $0.08B | $0.02B | 27.63% |
| 2020-06-30 | $0.07B | $0.02B | 30.14% |
| 2020-03-31 | $0.07B | $0.02B | 32.86% |
| 2019-12-31 | $0.07B | $0.02B | 35.38% |
| 2019-06-30 | $0.04B | $0.01B | 33.33% |
| 2019-03-31 | $0.04B | $0.01B | 28.57% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |